Compare Moderna, Inc. (MRNA) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Trade Desk Inc — how do they compare? Moderna, Inc. trades at $197.25 (market cap $78.65B), while Trade Desk Inc trades at $12.4 (market cap $5.83B). The key difference: Moderna, Inc. is far larger — about 13.5× Trade Desk Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Trade Desk Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Trade Desk Inc for 72 Days on average.
| MRNA | TTD | |
|---|---|---|
Market Cap | $78.65B | $5.83B |
Volume | 37,373,437 | 15,864,392 |
Sector | Health | Media |
52-Week High | $203.46 | $54.13 |
52-Week Low | $22.36 | $11.92 |
Typical Hold Time | 59 Days | 72 Days |
Enterprise Value | $74.80B | $4.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% amid Nasdaq-100 inclusion news, though it remains well below the analyst consensus target of $115.70. The stock shows bullish technical momentum with recent earnings beats, but faces fundamental challenges with negative profit margins and declining revenue from pandemic-era highs. The company's cash flow improved in 2025, turning positive for the first time since 2022, while its pipeline, including oncology vaccines, attracts investor interest despite valuation concerns.
Outlook: Near-term momentum from index fund buying and pipeline updates may support the stock, but high valuation multiples and persistent losses pose significant risks. Long-term growth depends on successful commercialization of non-COVID products, with current prices reflecting optimistic scenarios. Investors should weigh the potential of the mRNA platform against execution risks and competitive pressures.
TTD trades at $12.09, up 1.43% on the day but remains under pressure with a bearish technical signal. Revenue grew to $2.90B in 2025, though net income margin slipped to 15.3%. Recent earnings show volatility, with a Q2 beat but Q1 miss. The stock faces stiff competition and slowing growth, reflected in negative cash flow trends and a workforce reduction announced in September 2026.
The outlook is cautious; while valuation ratios appear low, competitive threats from tech giants and declining growth pose significant risks. Analyst consensus is mixed with a $14.72 price target, but the stock's 68% YTD drop underscores investor skepticism. Upside depends on execution in connected TV and new verticals like healthcare ads.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
